Dynamic trends in the sales of oral antidiabetic drugs in moldova: a four-year analysis (2018-2021)
DOI:
https://doi.org/10.52556/2587-3873.2024.5(102).14Keywords:
type 2 diabetes mellitus, oral antidiabetic drugs, market analysis, pharmacotherapy trendsAbstract
Type 2 Diabetes Mellitus (T2DM) remains a significant public health challenge worldwide and in the Republic of Moldova. Effective pharmacotherapy is critical for managing this condition. This study investigates the sales trends of oral antidiabetic drugs, reflecting their accessibility and implementation of newer medicines in clinical practice over four years - 20182021. A retrospective structural analysis of sales data for oral antidiabetic drugs was conducted using information collected from major pharmacy chains and non-network pharmacies across the Republic of Moldova. The analysis identified 24 trade names (10 international nonproprietary names + 3 combinations) used in the treatment of patients with T2DM. A significant increase in sales volume was observed both in terms of units (91.59%) and monetary value (71.28%) from 2018 to 2021, amidst a decreasing average price per package. Metformin dominated sales, showing a preference for established therapies, while newer drug classes such as SGLT2 inhibitors and DPP-4 inhibitors showed substantial growth. The Moldovan oral antidiabetic drug market has shown robust growth, driven by both traditional and innovative medicines. The decrease in average drug prices over the study period may indicate improved patient access to essential medications.
References
1. Mordor Intelligence: Diabetes Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022-2027). https://www.mordorintelligence.com/industry-reports/diabetes-drugs-market
2. Ministerul Sănătății al Republicii Moldova: Astăzi este marcată Ziua Mondială a Diabetului. https://ms.gov.md/comunicare/comunicate/astazi-este-marcata-ziua-mondiala-a-diabetului
3. ERIKSSON, J., ELIASSON, B., BENNET, L., SUNDSTRÖM, J. Registry-based randomised clinical trials: a remedy for evidence-based diabetes care? In: Diabetologia. 2022, nr. 65(10), pp. 1575-1586. https://doi.org/10.1007/s00125-022-05762-x
4. BACINSCHI, N., BACINSCHI, A., BACINSCHI-GHEORGH-ITA, S. Antidiabeticele orale: noi abordări în diabetul zaharat tip 2. În: Sănătate Publică, Economie și Man-agement în Medicină. 2018, nr. 4 (78), pp. 61-68.
5. Casa Națională de Asigurări Sociale din Republica Mol-dova: Lista medicamentelor compensate. http://www.cnam.md/index.php?page=295&
6. International Chamber of Commerce:ICC/ESOMAR International Code on Market, Opinion and Social Research and Data Analytics. 2016. https://iccwbo.org/news-publications/policies-reports/iccesomar-international-code-market-opinion-social-research-data-analytics
7. Catalogul național de prețuri de producător la medicamente. Agenția Medicamentului şi Dispozi-tivelor Medicale din Republica Moldova. https://amdm.gov.md/ro/page/catalog-national-de-preturi-de-producator-la-medicamente.
8. ANESTIADI, Z., VUDU, L. ALEXA, Z. et al. Protocol clinic național "Diabetul zaharat necomplicat" (PCN-33). Chişinău, 2019. 101 p. https://msmps.gov.md/wp-content/uploads/2021/02/PCN-33-DZ.pdf
9. Ghid de management al diabetului zaharat. Elaborat de către Societatea Română de Diabet, Nutriție şi Boli Metabolice, preşedinte prof. univ. dr. Romulus Timar şi Federația Română de Diabet, Nutriție şi Boli Metabo-lice, preşedinte prof. univ. dr. Gabriela Roman. 2021, 295 p. https://societate-diabet.ro/wp-content/uploads/2021/07/Ghidul-SRDNBM-2021.pdf
10. ERIKSSON, J., ELIASSON, B., BENNET, L., SUNDSTRÖM J. Registry-based randomised clinical trials: a remedy for evidence-based diabetes care? In: Diabetologia. 2022, nr. 65(10), pp. 1575-1586. https://doi.org/10.1007/s00125-022-05762-x
11. VOLKE, V., et al. Systematic review and meta-analysis of head-to-head trials comparing sulfonylureas and low hypoglycaemic risk antidiabetic drugs. In: BMC Endocr Disord. 2022, nr. 22(1), pp. 251. https://doi.org/10.1186/s12902-022-01158-5
12. MAZIN, I., et al. The Impact of Novel Anti-Diabetic Medications on CV Outcomes: A New Therapeutic Ho-rizon for Diabetic and Non-Diabetic Cardiac Patients. In: Journal of Clinical Medicine. 2022, nr. 11(7):1904. https://doi.org/10.3390/jcm11071904
13. COSENTINO, F., et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). In: European Heart Journal, 2020, nr. 41, pp. 255-323, https://doi.org/10.1093/eurheartj/ehz486
14. REHMAN, M.B., et al. Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: Meta-analysis of placebo-controlled randomized clinical trials. In: Diabetes Metab. 2017, nr. 43(1), pp. 48-58. https://doi.org/10.1016/j.diabet.2016.09.005
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
